Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year High – Here’s What Happened

Tyra Biosciences, Inc. (NASDAQ:TYRA) reached a new 52-week high during trading on Thursday . The stock traded as high as $17.99 and last traded at $17.7040, with a volume of 93445 shares trading hands. The stock had previously closed at $16.62.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on TYRA shares. Raymond James Financial initiated coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Oppenheimer reiterated an “outperform” rating and issued a $36.00 price target on shares of Tyra Biosciences in a report on Wednesday, September 10th. Finally, Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $32.00.

Tyra Biosciences Stock Performance

The business’s 50 day moving average is $14.13 and its 200 day moving average is $11.76. The company has a market capitalization of $953.86 million, a price-to-earnings ratio of -9.52 and a beta of 1.12.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.50). Sell-side analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds have recently made changes to their positions in TYRA. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Tyra Biosciences during the 1st quarter worth approximately $84,000. US Bancorp DE raised its stake in Tyra Biosciences by 50.5% during the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock worth $51,000 after purchasing an additional 1,823 shares during the period. Swiss National Bank raised its position in Tyra Biosciences by 42.0% in the first quarter. Swiss National Bank now owns 29,400 shares of the company’s stock valued at $273,000 after purchasing an additional 8,700 shares during the period. Nuveen LLC purchased a new position in Tyra Biosciences in the 1st quarter valued at approximately $465,000. Finally, American Century Companies Inc. lifted its position in shares of Tyra Biosciences by 5.8% during the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after purchasing an additional 1,289 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.